Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

عرض إصدارات أخرى (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
التنسيق:	Journal article
اللغة:	English
منشور في:	2001

مواد مشابهة

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
حسب: Croucher, P, وآخرون
منشور في: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
حسب: Croucher, P, وآخرون
منشور في: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
حسب: Croucher, P, وآخرون
منشور في: (2002)

Osteoprotegerin and the development of myeloma bone disease
حسب: Croucher, P, وآخرون
منشور في: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
حسب: Vanderkerken, K, وآخرون
منشور في: (2003)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
حسب: Shipman, C, وآخرون
منشور في: (2002)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
حسب: De Leenheer, E, وآخرون
منشور في: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
حسب: Shipman, C, وآخرون
منشور في: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
حسب: Croucher, P, وآخرون
منشور في: (2003)

Role of osteoprotegerin (OPG) in cancer.
حسب: Holen, I, وآخرون
منشور في: (2006)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
حسب: Croucher, P, وآخرون
منشور في: (2002)

Bisphosphonates--mechanisms of action in multiple myeloma.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
حسب: Shipman, C, وآخرون
منشور في: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
حسب: Shipman, C, وآخرون
منشور في: (2000)

The role of osteoprotegerin in breast and prostate cancer
حسب: Holen, I, وآخرون
منشور في: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
حسب: De Leenheer, E, وآخرون
منشور في: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
حسب: Shipman, C, وآخرون
منشور في: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
حسب: Shipman, C, وآخرون
منشور في: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
حسب: Holen, I, وآخرون
منشور في: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
حسب: Eaton, C, وآخرون
منشور في: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
حسب: Anđelković Zlatibor, وآخرون
منشور في: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
حسب: Huan Liu, وآخرون
منشور في: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
حسب: Mueller, G, وآخرون
منشور في: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
حسب: Mueller, G, وآخرون
منشور في: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
حسب: Edwards, C, وآخرون
منشور في: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
حسب: Holen, I, وآخرون
منشور في: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
حسب: Eaton, C, وآخرون
منشور في: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
حسب: Akshitha Devaraj, MBBS, وآخرون
منشور في: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
حسب: Aiken Dao, وآخرون
منشور في: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
حسب: Dongyeop Shin, وآخرون
منشور في: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
حسب: Locklin, R, وآخرون
منشور في: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
حسب: Waterman, E, وآخرون
منشور في: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
حسب: Dongzheng Gai, وآخرون
منشور في: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
حسب: Domingos Sousa, وآخرون
منشور في: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
حسب: Dirk Hose, وآخرون
منشور في: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
حسب: Lwin, S, وآخرون
منشور في: (2017)